Companies Merge to Form NeXstar
BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to form NeXstar Pharmaceuticals, Inc. One focus of the new company will be the liposomal delivery of oligonucleotides. The company's initial product, AmBisome, is a liposomal formulation of amphotericin B, which has been approved for marketing in 16 countries for the treatment of life-threatening systemic fungal infections that fail to respond to conventional amphotericin B therapy.
BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to formNeXstar Pharmaceuticals, Inc. One focus of the new company willbe the liposomal delivery of oligonucleotides. The company's initialproduct, AmBisome, is a liposomal formulation of amphotericinB, which has been approved for marketing in 16 countries for thetreatment of life-threatening systemic fungal infections thatfail to respond to conventional amphotericin B therapy.
A phase III trial of the product in conjunction with the NationalCancer Institute has recently been announced.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
